Cargando…

Novel Intriguing Strategies Attenuating to Sarcopenia

Sarcopenia, the age-related loss of skeletal muscle mass, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement, a decline in strength and power, increased risk of fall-related injury, and, often, frailty. Since sarcopenia is largely attributed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakuma, Kunihiro, Yamaguchi, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303581/
https://www.ncbi.nlm.nih.gov/pubmed/22500226
http://dx.doi.org/10.1155/2012/251217
_version_ 1782226758910607360
author Sakuma, Kunihiro
Yamaguchi, Akihiko
author_facet Sakuma, Kunihiro
Yamaguchi, Akihiko
author_sort Sakuma, Kunihiro
collection PubMed
description Sarcopenia, the age-related loss of skeletal muscle mass, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement, a decline in strength and power, increased risk of fall-related injury, and, often, frailty. Since sarcopenia is largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostasis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. Resistance training combined with amino acid-containing supplements is often utilized to prevent age-related muscle wasting and weakness. In this review, we summarize more recent therapeutic strategies (myostatin or proteasome inhibition, supplementation with eicosapentaenoic acid (EPA) or ursolic acid, etc.) for counteracting sarcopenia. Myostatin inhibitor is the most advanced research with a Phase I/II trial in muscular dystrophy but does not try the possibility for attenuating sarcopenia. EPA and ursolic acid seem to be effective as therapeutic agents, because they attenuate the degenerative symptoms of muscular dystrophy and cachexic muscle. The activation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in skeletal muscle by exercise and/or unknown supplementation would be an intriguing approach to attenuating sarcopenia. In contrast, muscle loss with age may not be influenced positively by treatment with a proteasome inhibitor or antioxidant.
format Online
Article
Text
id pubmed-3303581
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33035812012-04-12 Novel Intriguing Strategies Attenuating to Sarcopenia Sakuma, Kunihiro Yamaguchi, Akihiko J Aging Res Review Article Sarcopenia, the age-related loss of skeletal muscle mass, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement, a decline in strength and power, increased risk of fall-related injury, and, often, frailty. Since sarcopenia is largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostasis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. Resistance training combined with amino acid-containing supplements is often utilized to prevent age-related muscle wasting and weakness. In this review, we summarize more recent therapeutic strategies (myostatin or proteasome inhibition, supplementation with eicosapentaenoic acid (EPA) or ursolic acid, etc.) for counteracting sarcopenia. Myostatin inhibitor is the most advanced research with a Phase I/II trial in muscular dystrophy but does not try the possibility for attenuating sarcopenia. EPA and ursolic acid seem to be effective as therapeutic agents, because they attenuate the degenerative symptoms of muscular dystrophy and cachexic muscle. The activation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in skeletal muscle by exercise and/or unknown supplementation would be an intriguing approach to attenuating sarcopenia. In contrast, muscle loss with age may not be influenced positively by treatment with a proteasome inhibitor or antioxidant. Hindawi Publishing Corporation 2012 2012-02-20 /pmc/articles/PMC3303581/ /pubmed/22500226 http://dx.doi.org/10.1155/2012/251217 Text en Copyright © 2012 K. Sakuma and A. Yamaguchi. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sakuma, Kunihiro
Yamaguchi, Akihiko
Novel Intriguing Strategies Attenuating to Sarcopenia
title Novel Intriguing Strategies Attenuating to Sarcopenia
title_full Novel Intriguing Strategies Attenuating to Sarcopenia
title_fullStr Novel Intriguing Strategies Attenuating to Sarcopenia
title_full_unstemmed Novel Intriguing Strategies Attenuating to Sarcopenia
title_short Novel Intriguing Strategies Attenuating to Sarcopenia
title_sort novel intriguing strategies attenuating to sarcopenia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303581/
https://www.ncbi.nlm.nih.gov/pubmed/22500226
http://dx.doi.org/10.1155/2012/251217
work_keys_str_mv AT sakumakunihiro novelintriguingstrategiesattenuatingtosarcopenia
AT yamaguchiakihiko novelintriguingstrategiesattenuatingtosarcopenia